“In the first nine months of 2025, we continued to advance toward the potential initiation of Phase 3 trials for ORIC-944 in prostate cancer and enozertinib in lung cancer. The ORIC-944 Phase 1b data announced today further support its potential best-in-class efficacy and safety profile, and we look forward to sharing clinical data for enozertinib later this year that will highlight its best-in-class potential,” said Jacob M. Chacko, president and chief executive officer. “Backed by compelling clinical data and a strong cash position, we remain focused on rapidly advancing these programs to registrational studies and, ultimately, commercialization.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Is ORIC a Buy, Before Earnings?
- Promising Preclinical Data and Strategic Combinations Bolster Buy Rating for ORIC-944
- Oric Pharmaceuticals’ Promising Study on ORIC-944 for Metastatic Prostate Cancer
- Oric Pharmaceuticals’ Promising Study on ORIC-114 for Solid Tumors
- Oric Pharmaceuticals Advances in NSCLC Treatment with Phase 1b Study